The most common genetic alteration in the ALKBH5 gene were amplifications in the sarcomas (>8%), uterine carcinosarcomas, liver hepatocellular carcinoma and pancreatic adenocarcinomas; mutations (1.3%) in the bladder urothelial carcinomas; and deep deletions (>2%) in the diffuse large B-cell lymphomas (Figure 3A). Here, ALKBH5 is linked to bladder transitional cell carcinoma.